Chemotherapy and cancer vaccines given on the same day enhance antitumor responses in preclinical study

For cancer vaccines to work, immune cells need to recognize tumors and sustain their attack; chemotherapy, however, may damage these proliferating cells. Combining the two therapies is therefore more than a question of drug selection. A new study by the Oxford team at the Ludwig Institute for Cancer Research found that, in preclinical cancer models, certain chemotherapy treatments enhanced antitumor responses when given on the same day as a vaccine. This added benefit disappeared when the treatments were given several days apart.

Ludwig announced the study, published in *Cancer Cell*, on October 2. The team tested several chemotherapy drugs and found that the combination of carboplatin and paclitaxel, known as CarboTaxol, as well as cyclophosphamide, enhanced cancer vaccine activity in preclinical experiments. Information about the same study published by Medical Xpress also confirmed the paper's details, while Newswise republished the institutional announcement. The three sources do not represent independently obtained research evidence.

The effects of CarboTaxol were particularly sensitive to timing. The vaccine used in the study was administered as an initial dose and a booster dose, separated by several days. Giving chemotherapy on the same day as either dose improved vaccine effects. However, when chemotherapy and vaccination were separated by several days, the study no longer observed this benefit. This means that treatment scheduling may alter immune responses even when the same drugs are used.

The team further traced the findings to CD8-positive T cells expressing TCF1. CD8-positive T cells help attack cancer cells, while TCF1 is a factor that regulates gene expression and is associated with these cells' ability to maintain function, persist, and form immune memory. The study found that CarboTaxol expanded this cell population, and that this change did not depend on vaccination. The researchers suggest that it may provide a pool of immune cells that can be mobilized by stimulation with vaccine antigens.

When the team also added anti-PD-1 immune checkpoint inhibitor therapy, tumor control and survival improved further in preclinical models. This type of therapy helps sustain antitumor activity by blocking signals that suppress T-cell responses. However, the current results support the effects of the combination under specific experimental conditions and cannot be directly extrapolated to suggest that all chemotherapy treatments or cancer vaccines will have the same effects.

In human data, the researchers also observed an expansion of TCF1-positive CD8-positive T cells after CarboTaxol treatment in samples from two independent groups of cancer patients. This provides an additional human clue to the mechanism proposed by the animal experiments. However, changes in cells do not themselves equate to tumor shrinkage or improved survival, nor do they demonstrate that patients benefit from receiving chemotherapy and a vaccine on the same day.

The study raises a testable question for cancer vaccine trials: beyond selecting a treatment combination, should trial designs also account for the interval between chemotherapy and vaccination? The research team advocates further clinical evaluation of the three-way combination of a vaccine, chemotherapy, and anti-PD-1 therapy. Moving from enhanced immune responses to patient benefit still requires determining the applicable cancer and vaccine types, dosing schedules, and overall efficacy and safety.